VolitionRx Limited (VNRX)
NYSEAMERICAN: VNRX · Real-Time Price · USD
0.6200
-0.0072 (-1.15%)
At close: Aug 13, 2025, 4:00 PM
0.6200
0.00 (0.00%)
After-hours: Aug 13, 2025, 6:30 PM EDT
VolitionRx Revenue
VolitionRx had revenue of $246.39K in the quarter ending March 31, 2025, with 43.64% growth. This brings the company's revenue in the last twelve months to $1.31M, up 64.15% year-over-year. In the year 2024, VolitionRx had annual revenue of $1.23M with 59.10% growth.
Revenue (ttm)
$1.31M
Revenue Growth
+64.15%
P/S Ratio
43.23
Revenue / Employee
$15,392
Employees
85
Market Cap
63.87M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1.23M | 458.21K | 59.10% |
Dec 31, 2023 | 775.30K | 468.91K | 153.04% |
Dec 31, 2022 | 306.39K | 216.36K | 240.30% |
Dec 31, 2021 | 90.04K | 76.60K | 570.25% |
Dec 31, 2020 | 13.43K | -3.66K | -21.43% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
VNRX News
- 5 days ago - VolitionRx Limited Schedules Second Quarter 2025 Earnings Conference Call and Business Update - PRNewsWire
- 9 days ago - VolitionRx Announces Pricing of $1.2 Million Registered Direct Offering - PRNewsWire
- 4 weeks ago - Nu.Q® Discover Expands Global Adoption and Epigenetic Innovation - PRNewsWire
- 5 weeks ago - Volition Announces Groundbreaking Lateral Flow Test for Point-of-Care Quantification of Nucleosomes - PRNewsWire
- 2 months ago - Volition Announces MARS Consortium Clinical Study Suggests Nu.Q® H3.1. Concentrations are Closely Associated with Sepsis and Organ Failure - PRNewsWire
- 2 months ago - Volition Announces Two Oral Presentations at Asian Meeting of Animal Medicine Specialties - PRNewsWire
- 3 months ago - VolitionRx Limited Announces Successful Detection of Nucleosomes in Cats - PRNewsWire
- 3 months ago - VolitionRX Limited (VNRX) Q1 2025 Earnings Call Transcript - Seeking Alpha